Friday 16 October 2026
Export AVXL’s income statement to Excel — free account
Anavex Life Sciences Corp.
AVXL Healthcare Biotechnology
In the quarter to June 2026, EPS grew 150.0% and free cash flow grew 27.0%, each against the same quarter a year earlier.
1.31
0.17
−11.49%
Follow AVXL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
15.62 | 18.24 | 20.87 | 11.60 |
+8 more quarters Free account |
Net Debt/EBITDA |
(17.56) | 19.65 | 19.43 | 9.46 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(1.16) | 0.83 | 1.26 | 0.88 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.10) | (0.05) | (0.08) | (0.10) | |
Cash per Share |
1.28 | 1.37 | 1.48 | 1.20 | |
Shareholders Equity per Share |
1.21 | 1.31 | 1.42 | 1.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.21 | 1.31 | 1.42 | 1.11 | |
Free Cash Flow |
(9.10) | (4.44) | (7.15) | (8.60) | |
Working Capital |
112.45 | 121.71 | 126.62 | 94.87 | |
Net Current Asset Value |
112.45 | 121.71 | 126.62 | 94.87 | |
| Other line items | |||||
Quick Ratio |
15.51 | 18.18 | 20.81 | 11.56 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.10) | (0.05) | (0.08) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.91 | 0.80 | 1.70 | 1.63 | |
Average Payables |
5.20 | 4.76 | 3.60 | 6.94 | |
Average Assets |
111.29 | 122.95 | 128.52 | 119.69 | |
Average Common Equity |
101.70 | 110.73 | 118.77 | 107.57 |
Columns are period end dates